Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02998671 | Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne | PHASE2 | COMPLETED | 52 | — | — | Dec 22, 2016 | Aug 1, 2018 | Jul 12, 2022 | 10 | United States, Germany +1 |
Total inflammatory facial lesion count was the total count of papules, pustules and nodules assessed at day 85
| Arm | Type | Description |
|---|---|---|
| Group 1: CJM112 high dose | EXPERIMENTAL | CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2 |
| Group 2: CJM112 low dose | EXPERIMENTAL | CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2 |
| Group 3: Placebo, CJM112 low dose or high dose | PLACEBO_COMPARATOR | Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2 |
| Name | Type | Description |
|---|---|---|
| CJM112 | BIOLOGICAL | - |
| Placebo | OTHER | - |
Inclusion Criteria: * Male and female subjects aged 18 to 45 years of age included, and otherwise in good health as determined by medical history, physical examination, vital signs, ECGs and laboratory tests at screening. * Body weight between 50 and 120 kg, inclusive at screening. * Patients with ...